Benefits to test makers and users from the Medicare MolDx program have not been fully reaped, diagnostic reimbursement experts said at a recent Avalere summit.
The promise of Medicare’s MolDx program to provide greater reimbursement consistency and to fully reflect the value of molecular diagnostics has yet to be fulfilled, laboratory representatives argued at a diagnostics summit last month.
The Molecular Diagnostic Services, or MolDx, process for assessing CPT codes for reimbursement of lab tests “is taking more time...
A revised annex to the original decision also outlines expert remuneration limits and introduces further changes.
An upcoming US FDA advisory panel meeting will discuss adding a new indication to allow dermal fillers to be used in the upper chest, or décolletage. Plastic surgeons expect this could drive interest in the procedure, which is already performed off-label.
A system of pre-regulatory review consultations for innovative drugs and devices in South Korea has contributed to the accelerated development of such products.
HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.
A system of pre-regulatory review consultations for innovative drugs and devices in South Korea has contributed to the accelerated development of such products.
Thena Capital, the first UK-based early-stage specialist medtech firm, has made its first investment since closing its £50m fund. Medtech Insight spoke with general partner Pamela Walker Geddes to gain insight into Thena Capital’s investment strategy.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
